In an analysis from the Children’s Oncology Group phase III AALL1131 study reported in the Journal of Clinical Oncology, Alexander et al found that exposure...
In a systematic review and meta-analysis reported in JAMA Network Open, Banna et al found that neoadjuvant chemoimmunotherapy was associate...
The U.S. Food and Drug Administration (FDA) has approved trastuzumab-strf (Hercessi), a biosimilar to trastuzumab (Herceptin), for the treatment of...
On April 29, the U.S. Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv (Tivdak) for patients with recurrent...
Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer. The USPSTF now recommends...
ASCO and the oncology community are deeply saddened by the death of medical oncologist Worta J. McCaskill-Stevens, MD, MS, on November 15, 2023. Dr. McCaskill-Stevens served as Chief of the National Cancer Institute (NCI) Community Oncology and Prevention Trials Research Group and Director of the...
A novel chimeric antigen receptor (CAR) natural killer (NK)-cell therapy may be effective at treating patients with relapsed or refractory B-cell malignancies, according to a novel study published by Marin et al in Nature Medicine. Study Methods and Results In the new phase I/II trial,...
For patients with fully resectable pancreatic cancer, a minimally invasive surgical approach—laparoscopic or robotic—was shown to be comparable to open distal pancreatectomy in the multicenter randomized phase III DIPLOMA trial. These results were presented at the 2023 ASCO Annual Meeting and at a...
For the third year in a row, more than 250 leaders in cancer care, including cancer center directors, physicians, scientists, ethicists, journalists, public officials, and patient advocates, gathered at the Richard Nixon Presidential Library and Museum in Yorba Linda, California, to attend the...
23andMe has announced that the company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report. The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be ...
City of Hope recently announced the appointment of John D. Carpten, PhD, as Director of the National Cancer Institute (NCI)-designated comprehensive cancer center, Director of Beckman Research Institute of City of Hope, and Chief Scientific Officer. Dr. Carpten will also hold the Irell &...
In a phase II trial (NCI Protocol 10250) reported in the Journal of Clinical Oncology, Ingham et al found that the combination of olaparib and temozolomide showed activity in previously treated patients with advanced uterine leiomyosarcoma. Study Details In the multicenter trial, 22 evaluable...